SCHEMBL120800

SCHEMBL120800

CCC(N)(N)CCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11327625 0.80 SMN1; SMN2 (0.41)
SCHEMBL29141433 0.79
SCHEMBL27869315 0.78 LMNA (0.43)
Ammonia Solution, Strong SCHEMBL28031318 0.77 FDPS (0.37)
SCHEMBL2230611 0.75
SCHEMBL6888639 0.75 MEN1 (0.37)
SCHEMBL29141404 0.75 FDPS (0.43)
SCHEMBL56859 0.73
SCHEMBL2773862 0.73
SCHEMBL4644554 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 582 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115066238-A Preparation of cannabichromenes and related cannabinoids 海湾医学公司 2022-09-16 CN claimed
CN-1922324-B Bacterial virulence factors and uses thereof UNIV BRITISH COLUMBIA 2010-06-09 CN claimed
EP-1572074-A4 STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM UNITED BIOMEDICAL INC (US) 2008-04-30 EP claimed
EP-1465639-A4 ADJUVANT FORMULATIONS FOR BACTERIAL AND VIRUS VACCINES AND METHOD OF MAKING SAME IRX THERAPEUTICS INC (US) 2006-05-24 EP claimed
EP-1572074-A2 STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM United Biomedical, Inc. (US) 2005-09-14 EP claimed
US-20050148538-A1 Adjuvant formulations for bacterial and virus vaccines and method of making same IRX THERAPEUTICS, INC. 2005-07-07 US claimed
EP-1465639-A2 ADJUVANT FORMULATIONS FOR BACTERIAL AND VIRUS VACCINES AND METHOD OF MAKING SAME Immuno-RX, Inc. (US) 2004-10-13 EP claimed
EP-1092737-B1 Catalyst composition for the production of a polyurethane resin, and method for producing a polyurethane resin TOSOH CORP (JP) 2003-09-24 EP claimed
WO-2003068169-A2 STABILIZED SYNTHETIC IMMUNOGEN DELIVERY SYSTEM UNITED BIOMEDICAL INC. (US) 2003-08-21 WO claimed
WO-2003049670-A2 ADJUVANT FORMULATIONS FOR BACTERIAL AND VIRUS VACCINES AND METHOD OF MAKING SAME IMMUNO-RX, INC. (US) 2003-06-19 WO claimed
US-12042531-B2 Breast and ovarian cancer vaccines UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2024-07-23 US disclosed
CN-114504640-B Adjuvant containing risedronate zinc-aluminum and application thereof 厦门大学 2024-06-25 CN disclosed
US-20240050553-A1 MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS Seqirus UK Limited (GB) 2024-02-15 US disclosed
US-11896660-B1 Reducing hospitalization in elderly influenza vaccine recipients Seqirus UK Limited (GB) 2024-02-13 US disclosed
US-20240034773-A1 RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-02-01 US disclosed
WO-1993011792-A1 RECOMBINANT BOVINE HERPESVIRUS TYPE 1 POLYPEPTIDES AND VACCINES UNIVERSITY OF SASKATCHEWAN (CA) 1993-06-24 WO disclosed
EP-0527977-A1 NEMATODE VACCINE. BIOTECH AUSTRALIA PTY LTD (AU) 1993-02-24 EP disclosed
US-5151267-A Bovine herpesvirus type 1 polypeptides and vaccines UNIVERSITY OF SASKATCHEWAN (CA) 1992-09-29 US disclosed
WO-1992013889-A1 NEMATODE VACCINE BIOTECH AUSTRALIA PTY. LIMITED (AU) 1992-08-20 WO disclosed
WO-1985000976-A1 METHOD AND MATERIALS FOR DEVELOPMENT OF IMMUNOLOGICAL RESPONSES PROTECTIVE AGAINST MALARIAL INFECTION UNIVERSITY OF ILLINOIS (US) 1985-03-14 WO disclosed